Caris Life Sciences (CAI) news
Recent news
Caris Life Sciences, Inc.: JP Morgan cuts target price to $25 from $30 (fixes typo)
AInvest Wire · Aug 6, 2026Caris Life Sciences, Inc.: JP Morgan cuts target price to $25 from $30
Caris Life Sciences (NASDAQ: CAI) has seen its price target reduced by JPMorgan Chase & Co. from $35.00 to $30.00, according to a recent research note . This adjustment reflects a more cautious outlook from the investment bank, despite maintaining an "overweight" rating for the stock. The updated…
AInvest Wire · Aug 6, 2026Caris Life Sciences Inc Q2 net loss per share $0.00
Caris Life Sciences Inc. reported a net loss per share of $0.00 for the second quarter of 2026, indicating a break-even performance on a per-share basis during the period[1]. This result reflects the company’s financial position amid ongoing operations in the life sciences sector. Investors and…
AInvest Wire · Aug 5, 2026Caris Life Sciences - shares to trade on both Nasdaq and NYSE Texas under CAI ticker
AInvest Wire · Jun 16, 2026Caris Life Sciences announces dual listing on NYSE Texas
Caris Life Sciences, a patient-centric AI TechBio company specializing in precision medicine, has announced its dual listing on the Nasdaq Global Select Market under the ticker symbol “CAI” following the successful pricing of its IPO on June 17, 2025. The company issued 23,529,412 shares at $21.00…
AInvest Wire · Jun 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.